Optimizing ATMP Cryopreservation: How IntegriCell™ Services In Belgium Ensure Cell Viability And Supply Chain Integrity

Cryopreservation is rapidly emerging as a vital, yet often overlooked, element of the Advanced Therapy Medicinal Product (ATMP) supply chain. The effectiveness of cell-based therapies hinges on preserving cell viability, stability, and consistency. However, inconsistencies in cryopreservation methods have undermined therapeutic success.

Many ATMP developers face challenges such as inconsistent freezing protocols, logistical delays, and regulatory obstacles, all of which can negatively affect product quality. To tackle these issues, Cryoport Systems introduced the IntegriCell™ Cryopreservation Center in Villers-le-Bouillet, Belgium, in 2024. This facility, in conjunction with the IntegriCell™ cryopreservation services at our Global Supply Chain Center in Houston, TX, offers standardized, validated cryopreservation solutions. These solutions ensure the consistent, compliant delivery of high-quality leukapheresis starting material, crucial for cell-based therapies. Our services guarantee that each batch meets the rigorous standards necessary for successful therapeutic outcomes, reducing variability and improving reliability. By standardizing protocols, we address the stability challenges of fresh donor-derived cellular material, optimizing manufacturing efficiency and simplifying operations.